GlassScriptPhysician profile
Anneliese Provost
NPI 1184173635
$2,189.79
in general payments reported to CMS, 2019-2025
21 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $582 · 2023: $503 · 2024: $453 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $588.44 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $411.41 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $335.51 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $204.78 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $152.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $88.74 | 2022-2025 | Trelegy Ellipta |
| Abbott Laboratories | $55.41 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $39.52 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Bayer Healthcare Pharmaceuticals INC. | $38.22 | 2022 | |
| Amarin Pharma, INC. | $34.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.42 | 2023 | |
| Renalytix Ai, INC. | $27.04 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $24.85 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $23.48 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $23.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.40 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.13 | 2025 | Voquezna |
| Pfizer INC. | $19.84 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $19.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.60 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anneliese Provost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.